Will the Capital Markets Open in 2025 for Life Sciences?
By Sandra Gardiner
For the past several years, life science executives and investors alike have been asking the same question: when will the capital markets fully reopen? After a challenging 2022–2023 cycle marked by inflation, rising interest rates, and geopolitical uncertainty, many hoped 2024 would bring a meaningful rebound. Instead, the year proved…Read More
Read MoreScaling for Growth: Building a Foundation for Your Company’s Next Inflexion Point
By Sandra Gardiner
My career as a finance executive in both biotech and medtech Life Sciences companies has included many assignments where growth was imperative, despite prevailing countercurrents in the market and the challenges this imposed internally: At Lipid Sciences, a privately held biotechnology company pursuing HDL therapies for cardiac and viral applications,…Read More
Read More